Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor

Haemostasis

Volumn 28, Issue 5, 1998, Pages 229-235

  Altman, Raul ^a   Scazziota, Alejandra ^a   Rouvier, Jorge ^a  

^a Centro de Trombosis de Buenos Aires   (Argentina)

Author keywords

Heparin, low molecular weight; Heparin, unfractionated; Tissue factor pathway inhibitor, free; Tissue factor pathway inhibitor, total

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 9A; ENOXAPARIN; HEPARIN; HEPARIN CALCIUM; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD SAMPLING; DOSE TIME EFFECT RELATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME INACTIVATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

EID: 0032321730     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000022436     Document Type: Article

References (25)

1. Gurfinkel EP, Manos EJ, Mejail IR, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
2. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
3. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, Stephens J, Weatherley B, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group: A com-parison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
4. Abildgaard U, Sandset P, Lindahl A: Tissue factor pathway inhibitor, in Poller L (ed): Recent Advances in Blood Coagulation. Edinburgh, Churchill Livingstone, 1993, pp 105-124.
5. Perez-Requejo JL, Lucena-Solano O, Perez-Garcia M, Santarelli MT: Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin). Thromb Haemost 1997;78:PS1172.
6. Hirsh J: In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding. Haemostasis 1986;16:82-86.
7. Hemker HC, Beguin S, Kakkar VV: Can the haemorrhagic component of heparin be identified? Or an attempt at clean thinking on a dirty drug. Haemostasis 1996;26:117-126.
8. Fareed J, Jeske W, Eschenfelder V, Iqbal O, Hoppensteadt D, Ahsan A: Preclinical studies on a low molecular weight heparin. Thromb Res 1996;81:S1-S27.
9. Barrowcliffe TW, Merton RE, Havercroft SJ, Thunberg L, Lindahl U, Thomas DP: Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984;34:125-134.
10. Sandset PM, Bendz B: Tissue factor pathway inhibitor: Clinical deficiency states. Thromb Haemost 1997;78:467-470.
11. Zitoun D, Bara L, Bloch MF, Samama MM: Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res 1994;75:577-580.
12. Novotny WF, Brown SG, Miletich JP, Rader DJ, Bronze GJ: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
13. Hoppensteadt DA, Walenga JM Fasanella A, Jeske W, Fareed J: TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175-185.
14. Levine D, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, Geerts W, Kassis J, Desjardins L, Cusson J, Cruickshank M, Powers P, Brien W, Haley S, Willan A: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1966;334:677-681.
15. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, D'Azemar P, Buller HR, for the TASMAN Study Group: Treatment of venous thrombosis with intravenous unfractioned heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687.
16. Neri Serneri GG, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L, Rostagno C, Tamburini C, Carnovali M, Magnani B, for the Studio Eparine Sottocutanea nell'Angina Instabile (SESAIR) Refrattorie Group: Randomized comparison of subcutaneous heparin, intravenous heparin and aspirin in unstable angina. Lancet 1995;345:1201-1204.
17. Studio sulla calciparina nell'angina e nella trombosi ventriculare nell'infarto Group: Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;ii:182-186.
18. Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hansen TA, Nordoy A: Effect of cholesterol lowering on intravascular pool of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995;15:879-885.
19. Lindahl AK, Abidgaard U, Larsen ML, Aamodt LM, Nordfang O, Beck TC: Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991(suppl 14):39-48.
20. Ariëns RA, Faioni EM, Manucci PM: Repeated release of tissue factor pathway inhibitor. Thromb Haemost 1994;72:327-328.
21. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A: Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996;76:703-709.
22. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Østergaard P, Nordoy A: Differential effect of low molecular weight (LMWH) and unfractionated (UFH) heparin on intravascular TFPI: A proposed mechanism for difference in antithrombotic action. Thromb Haemost 1997;78:4.
23. Berrettini M, Ascani A, Parise P, Morini M, Malaspina M, Zanuttini F, Nenci GG: The release of tissue factor pathway inhibitor (TFPI) in patients receiving prophylactic antithrombotic regimens with unfractionated heparin or LMWH (reviparin). Thromb Haemost 1997;78:410.
24. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B, for the THESSE Study Group: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
25. Fiessinger JN, Lopez Fernandez M, Gatterer E, Grandqvist S, Kher A, Olsson CG, Söderberg K: Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-199.